CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
COMPUGEN LTD
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 2, 2026
$1.97+0.01 (+0.51%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 5.2
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
87.3%−9.7 pts over 5 years
Operating margin
43.1%+1617.9 pts over 5 years
Net margin
48.6%+1533.5 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +161.1% | +113.3% | +105.2% | +22.9% | |
| Gross profit | +218.6% | +113.5% | +100.9% | +23.6% | |
| Free cash flow | -36.7% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -41.1% | -37.6% | 44.8% | |
| Return on assets | -37.0% | -30.9% | 26.0% | |
| Current ratio | 13.22 | 12.27 | 6.56 | |
| Capex to revenue | 365.0% | 8.3% | 0.4% | |
| Diluted shares | 51M | 80M | 94M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Compugen generated $173.93M from operations and spent $1.37M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$173.93M
Used
$1.37M
Capital expenditure$1.37M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin48.6%
×Asset turnover0.54×
×Equity multiplier1.72×
=Return on equity, FY202544.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 48.6% | 0.54× | 1.72× | 44.8% |
| FY2024 | -51.1% | 0.24× | 1.96× | -23.6% |
| FY2023 | -56.1% | 0.31× | 1.50× | -26.2% |
| FY2022 | -449.3% | 0.07× | 1.23× | -36.5% |
| FY2021 | -570.0% | 0.04× | 1.19× | -30.2% |
| FY2020 | -1484.9% | 0.02× | 1.21× | -37.6% |
| FY2018 | -127.0% | 0.39× | 1.38× | -67.9% |
| FY2016 | -4425.0% | 0.01× | 1.11× | -41.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$35.34M
- Cash generatingOperating cash flow above zero$31.63M
- Return on assets improvedROA up on the prior year-11.7% → 30.7%
- Earnings backed by cashOperating cash flow above net income$31.63M vs $35.34M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.26 → 6.56
- No dilutionShare count did not rise90M → 94M
- Gross margin improvedGross margin up on the prior year71.54% → 87.29%
- More efficientAsset turnover rose0.23 → 0.63